文献速递头颈外科

扁桃体鳞癌的术前诱导化疗

Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil.
PubMed 文献 · Laryngoscope · 2019-07-18

本研究回顾性分析38例接受顺铂联合多西他赛诱导化疗后行颈清扫及根治性扁桃体切除术的扁桃体鳞癌患者。中位随访4.1年,45%达完全缓解,76%治疗成功;吸烟状态是预后主要驱动因素,HPV状态和T分期也重要;HPV阳性非吸烟者预后极佳。

要点

  • 诱导化疗后手术是扁桃体鳞癌可行方案,HPV阳性非吸烟者预后极佳。
  • 吸烟状态是预后主要驱动因素,HPV状态和T分期也重要。
  • 治疗失败者挽救机会差,无论后续治疗类型。

核心结论

  • 除HPV阴性吸烟者外,诱导化疗后手术联合选择性放化疗是扁桃体鳞癌的可行治疗选择。

研究设计与样本

  • 回顾性队列研究,纳入38例接受顺铂和多西他赛诱导化疗后行颈清扫和根治性扁桃体切除术的扁桃体鳞癌患者。

主要发现

  • 45%(17例)患者对诱导化疗达完全缓解。
  • 76%(29/38)患者治疗成功:53%(20/38)仅化疗和手术,24%(9/38)需术后放化疗。
  • HPV阳性患者中近90%(23/26)无疾病证据,HPV阴性患者中一半(6/12)无疾病证据,HPV状态为显著预后因素(P = .02)。
  • 当前吸烟者仅38%(5/13)无疾病证据,非吸烟者96%(24/25)无疾病证据(P = .0002)。
  • 所有HPV阳性非吸烟者(20/20)末次随访时无疾病证据。

关键数值与推荐

  • 完全缓解率45%(17例)。
  • HPV状态预后差异P = .02。
  • 吸烟状态预后差异P = .0002。

临床怎么用

  • 对扁桃体鳞癌可考虑诱导化疗后手术联合选择性放化疗,尤其HPV阳性非吸烟者。
  • 吸烟状态应作为重要预后因素纳入治疗决策。
  • 治疗失败者挽救机会差,需重视初始治疗选择。

局限性

  • 回顾性研究,样本量较小(38例),证据等级为4。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: The indications for and efficacy of induction chemotherapy in the management of squamous cell carcinoma of the head and neck is controversial. With the advent of human papillomavirus (HPV)-related cancers, survival has improved significantly. Here we present a group of patients with tonsil cancer treated with induction chemotherapy followed by surgery. STUDY DESIGN: Retrospective cohort study. METHODS: Thirty-eight patients with tonsil cancer were treated with induction chemotherapy, consisting of cisplatin and docetaxel, followed by neck dissection and radical tonsillectomy. Twenty-six patients were HPV+, 28 were nonsmokers or long-term former smokers, and 28 were T1/T2. Fourteen patients required postoperative chemoradiotherapy (CRT). Median follow-up time was 4.1 years. RESULTS: A complete response to induction chemotherapy was achieved in 45% (17) of patients. In total, 76% (29/38) of patients were successfully treated: 53% (20/38) with chemotherapy and surgery alone, and 24% (9/38) required postoperative CRT. Almost 90% (23/26) of HPV+ and half (6/12) of HPV- patients are no evidence of disease (NED). HPV status is a significant prognostic factor (P = .02). Only 38% (5/13) of current smokers were NED compared to 96% (24/25) of nonsmokers (P = .0002). All HPV+ nonsmokers (20/20) were NED at last follow-up. CONCLUSIONS: In this study, the primary driver of prognosis was smoking status. HPV status and T stage were also important. The prognosis for HPV+ nonsmokers is extremely good; most likely regardless of treatment. Treatment failures have a poor chance of salvage, irrespective of treatment type. With the major exception of HPV- smokers, induction chemotherapy followed by surgery with selective CRT is a viable treatment option for tonsil cancer. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:1206-1211, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Burke MS, Loree JT, Popat SR, et al. Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil. Laryngoscope. 2019. PMID: 31318046. doi:10.1002/lary.28180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。